IJR News — today's news from every side
block
verse
w
o
rdys
billionaire
.ai
your
list
Whiteboard
App
quizie
un
school
New Journal
Loading
Ask Genius
Apps
News
Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News
Encouragement
Video
Meme Wars
Brands
Yourlist
Quizie
F
FaithTap
B
Blessed
All brands
Ask Genius
Apps
Trending
Novartis Phase 3 Pelacarsen Trial Misses Cardiovascular Endpoint
x/novartis
— Sep 5, 2026
Novartis reported that the Phase III Lp(a)HORIZON trial did not meet its primary endpoint, showing that lowering Lp(a) with pelacarsen reduced levels but did not significantly reduce cardiovascular events in approximately 8,000 patients on guideline-directed therapy; the company said full data will be presented at a future medical congress. Meanwhile, Royalty Pharma outlined its financial stance on the pelacarsen investment, noting the trial’s failure won’t derail its recovery of invested funds and that royalties on Spinraza remain a key part of its portfolio as it pursues its 2030 receipts target, with Ionis royalties potentially reverting after a defined cap. The developments reflect a broader scientific and market reevaluation of Lp(a)-targeted therapies and their commercial prospects.
+3
3
Share
Jared Kim
Wonder how many other Lp(a) drugs in the pipeline just got a lot riskier to fund after this readout.
